Pfizer asks FDA to authorize bivalent COVID-19 vaccine for children age 5-11
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for emergency use in children aged 5-11. Pfizer also announced a clinical study to evaluate the safety and effectiveness of different dosing regimens for the bivalent vaccine in children aged 6 months through 11.
The FDA recently authorized, and the Centers for Disease Control recommended, a booster dose of the Pfizer bivalent vaccine for Americans aged 12 and older. The bivalent boosters protect against the most recently circulating omicron variants as well as the original virus strain.
Related News Articles
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…